Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma
Frontiers in Endocrinology · 08.05.2026 · 17
DOI: 10.3389/fendo.2026.1747769 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 08.05.2026. Verfasst von Yi Ruan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine Changde Hospital Xiangya School of Medicine Central South University (The first people's hospital of Changde city), Ch…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Lymphatic Metastasis, Thyrotropin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Differentiated thyroid carcinoma (DTC) is a common endocrine malignancy, and cervical lymph node metastasis (LNM) represents the predominant pattern of disease recurrence. For patients who develop persistent or recurrent cervical lesions following total thyroidectomy and radioactive iodine (131I) therapy, conventional reoperation or additional 131I therapy often provides limited efficacy and may carry increased procedural risks.
Methods
This single-center retrospective cohort study included 238 patients with persistent or recurrent cervical LNM after prior thyroidectomy and 131I therapy who were treated between January 2020 and January 2024. Among them, 118 patients received 125I seed implantation with thyroid-stimulating hormone (TSH) suppression. After 1:1 propensity score matching (PSM), 110 patients were included in each group for analysis. Short-term efficacy, thyroglobulin (Tg), radiologic changes, dosimetric consistency, survival outcomes, and adverse events were compared. Dynamic changes in Tg levels and the short-axis diameter of LNM were analyzed using a linear mixed-effects model.
Results
After PSM, the partial response rates at 6 and 12 months were significantly higher in the 125I+TSH group. 125I+TSH therapy was an independent predictor of partial response. Patients in the 125I+TSH group exhibited a faster decline in Tg levels, with an average reduction of approximately 14.5% per month and a reduction in the short-axis diameter of LNM of 4.8% per month, corresponding to biochemical and morphological half-lives of 4.4 and 14.2 months, respectively. The overall incidence of adverse events was low.
Conclusions
125I seed implantation combined with TSH suppression therapy accelerates Tg decline and lesion regression and demonstrates good safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine Changde Hospital Xiangya School of Medicine Central South University (The first people's hospital of Changde city), Changde, Hunan, China.
- Department of Radiological Physics Technology The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University (Hunan Cancer Hospital), Changsha, Hunan, China.
Zitieren
APA
Ruan, Y., Yuan, H., Zheng, F., Yang, Y., Chen, X., & Xu, C. (2026). Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1747769
Vancouver
Ruan Y, Yuan H, Zheng F, Yang Y, Chen X, Xu C. Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1747769
BibTeX
@article{Ruan2026,
author = {Ruan, Yi and Yuan, Hui and Zheng, Feng and Yang, Yang and Chen, Xuehua and Xu, Cheng},
title = {Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1747769}
}
EUVIMED